The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML

Bromodomain and extra-terminal (BET) protein inhibitors have been reported as treatment options for acute myeloid leukemia (AML) in preclinical models and are currently being evaluated in clinical trials. This work presents a novel potent and selective BET inhibitor (BI 894999), which has recently e...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerlach, Daniel, Tontsch-Grunt, Ulrike, Baum, Anke, Popow, Johannes, Scharn, Dirk, Hofmann, Marco H., Engelhardt, Harald, Kaya, Onur, Beck, Janina, Schweifer, Norbert, Gerstberger, Thomas, Zuber, Johannes, Savarese, Fabio, Kraut, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955861/
https://www.ncbi.nlm.nih.gov/pubmed/29491412
http://dx.doi.org/10.1038/s41388-018-0150-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955861/
https://www.ncbi.nlm.nih.gov/pubmed/29491412
http://dx.doi.org/10.1038/s41388-018-0150-2

Ejemplares similares